Delving into the Latest Updates on Komipharm International Co., Ltd. with Synapse

概览

关联

1

项与 Komipharm International Co., Ltd. 相关的药物

Sodium metaarsenite(Komipharm)

靶点

Telomerase

作用机制

端粒末端转移酶抑制剂

在研机构-

原研机构

Komipharm

在研适应症

肝细胞癌 [+1]

非在研适应症

胆管癌 [+7]

最高研发阶段临床2期

首次获批国家/地区-

首次获批日期-

2

项与 Komipharm International Co., Ltd. 相关的临床试验

ACTRN12622000958785

/ Not yet recruiting临床1期

Phase 1, Open-label, Two-Cohort Study of Orally Administered PAX-1 in Patients with Moderate COVID-19

开始日期2022-09-30

申办/合作机构

Komipharm International Australia Pty Ltd.

ACTRN12618001304224

/ Not yet recruitingN/A

A Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase II Study to Assess the Opioid-Sparing Activity of PAX-1 in Patients with Persistent Cancer Pain.

开始日期2018-09-28

申办/合作机构

Komipharm International Australia Pty Ltd.

100 项与 Komipharm International Co., Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Komipharm International Co., Ltd. 相关的专利（医药）

登录后查看更多信息

18

项与 Komipharm International Co., Ltd. 相关的文献（医药）

2024-05-01·Veterinary Pathology

PD-L1 mRNA and protein expression in canine mammary carcinomas: Correlation with histopathological grade and molecular markers

Article

作者: Seung, Byung-Joon ; Sur, Jung-Hyang ; Ko, Yeong-Ung ; Bae, Min-Kyung ; Choe, Nong-Hoon

Programmed death ligand 1 (PD-L1) is an immune checkpoint molecule that plays a crucial role in regulating antitumor immune responses. Canine mammary carcinomas (CMCs) are common tumors of dogs. Despite extensive studies on the heterogeneity of CMCs, there is still a lack of effective precision therapies for the treatment of CMCs. In this study, we aimed to investigate the correlation between PD-L1 mRNA and protein expression in CMCs and explore its association with histopathological grade and molecular markers, including the estrogen receptor, epidermal growth factor receptor 2, and cytokeratin 5/6 (CK5/6). Formalin-fixed paraffin-embedded samples were evaluated for PD-L1 mRNA expression using RNA in situ hybridization and PD-L1 protein expression using immunohistochemistry. We observed no substantial correlation between PD-L1 mRNA and protein expression in CMCs; however, PD-L1 mRNA levels were significantly higher in grade 3 than in grade 1 tumors ( P = .001). In addition, we observed a positive correlation between PD-L1 protein expression and CK5/6 expression in CMCs ( P = .032). These findings suggest that PD-L1 expression in CMCs is heterogeneous and may be regulated post-transcriptionally. Further studies are needed to explore the prognostic and therapeutic implications of PD-L1 expression in different molecular subtypes of CMCs and their potential as predictive biomarkers for immunotherapy.

2020-09-01·Expert Opinion on Investigational Drugs2区 · 医学

Phase I clinical trial of KML001 monotherapy in patients with advanced solid tumors

2区 · 医学

Article

作者: Park, Young Suk ; Lee, Jeeyun ; Ahn, Jin Seok ; Sun, Jong Mu ; Kim, Jungryul ; Ahn, Myung-Ju ; Park, Joon Oh ; Kim, Seokuee ; Han, RaeO ; Kim, Sujong ; Lim, Ho Yeong ; Kang, Won Ki

BACKGROUNDWe evaluated the tolerability, pharmacokinetics (PK) and preliminary efficacy of KML001, an oral trivalent arsenical, as a monotherapy in patients with advanced solid tumors.RESEARCH DESIGN AND METHODSWith a standard 3 + 3 design for dose-escalation stage, the planned dose levels of KML001 were 5, 7.5, 10, 12.5, and 15 mg/day for 28 days. Once the maximum tolerated dose was determined, 22 subjects were additionally enrolled for dose-expansion stage. PK analysis was performed in the 5, 10, and 15 mg/day cohort at the dose-escalation stage and also at the dose-expansion stage. Moreover, response was assessed using the standard RECIST 1.1.RESULTSA total of 45 Korean subjects were enrolled. No DLT was reported at the dose-escalation stage. Three DLTs, two cases of prolonged QTc interval and one of neutropenia, were reported in the 12.5 mg/day cohort at the dose-expansion stage. Higher total daily doses up to 12.5 mg/day of KML001 resulted in higher trough plasma concentrations. Among the 18 subjects who completed 2 cycles of therapy, 15 had progressive disease and 3 had stable disease.CONCLUSIONSDoses equal to or greater than 10 mg/day KML001 alone were tolerable and produced plasma concentrations higher than biologically relevant targets.

2019-12-01·Experimental & Molecular Medicine2区 · 医学

Intracellular sensing of viral genomes and viral evasion

2区 · 医学

ReviewOA

作者: Lee, Jong-Soo ; Chathuranga, Kiramage ; Lee, Hyun-Cheol

AbstractDuring viral infection, virus-derived cytosolic nucleic acids are recognized by host intracellular specific sensors. The efficacy of this recognition system is crucial for triggering innate host defenses, which then stimulate more specific adaptive immune responses against the virus. Recent studies show that signal transduction pathways activated by sensing proteins are positively or negatively regulated by many modulators to maintain host immune homeostasis. However, viruses have evolved several strategies to counteract/evade host immune reactions. These systems involve viral proteins that interact with host sensor proteins and prevent them from detecting the viral genome or from initiating immune signaling. In this review, we discuss key regulators of cytosolic sensor proteins and viral proteins based on experimental evidence.

100 项与 Komipharm International Co., Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Komipharm International Co., Ltd. 相关的转化医学

登录后查看更多信息